TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial
Brief Summary: The aim of the study is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction of hospitalizations and mortality (primary safety endpoint) in elderly patients with chronic heart failure. The intervention, consisting of regular contacts with the local pharmacy and weekly dosing aids, aims to improve medication adherence and management.


Options:
A: Arm Label: Traditional CERSG Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Health Worker Diabetes Education: Print media | Arm Label: Web-Based Materials Arm; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Diabetes Education: tailored web site | Intervention Type: BEHAVIORAL; Name: Community Health Worker Diabetes Education: Print media; Assigned to Arm(s): Traditional CERSG Arm | Intervention Type: BEHAVIORAL; Name: CHW Diabetes Education: tailored web site; Assigned to Arm(s): Web-Based Materials Arm
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes Peer Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Peer Counseling | Intervention Type: BEHAVIORAL; Name: Diabetes Peer Counseling; Assigned to Arm(s): Diabetes Peer Counseling
C: Arm Label: regular, pharmacy-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Regular, pharmacy based intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Regular, pharmacy based intervention; Assigned to Arm(s): regular, pharmacy-based intervention
D: Arm Label: Free and convenient medicine access; Type: EXPERIMENTAL; Interventions: Other: Free and convenient medicine access | Arm Label: Usual medicine access; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Free and convenient medicine access; Assigned to Arm(s): Free and convenient medicine access

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset
Brief Summary: To evaluate the hypothesis that mechanical embolectomy with the Solitaire FR device is superior to medical management alone in achieving favorable outcome in the distribution of the modified Rankin Scale scores at 90 days in subjects presenting with acute large vessel ischemic stroke \< 8 hours from symptom onset.


Options:
A: Arm Label: Best standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best standard treatment | Arm Label: Mechanical thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mechanical thrombectomy | Intervention Type: PROCEDURE; Name: mechanical thrombectomy; Assigned to Arm(s): Mechanical thrombectomy | Intervention Type: DRUG; Name: Best standard treatment; Assigned to Arm(s): Best standard treatment
B: Arm Label: thrombectomy; Type: EXPERIMENTAL; Interventions: Procedure: Thrombectomy, Device: Stentriever Solitaire FR® or Penumbra System® | Arm Label: best medical treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Thrombectomy; Assigned to Arm(s): thrombectomy | Intervention Type: DEVICE; Name: Stentriever Solitaire FR® or Penumbra System®; Assigned to Arm(s): thrombectomy
C: Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Solitaire FR device | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: DEVICE; Name: Solitaire FR device; Assigned to Arm(s): Endovascular treatment | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical treatment
D: Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Arm Label: IV rtPA and IA Penumbra System; Type: EXPERIMENTAL; Interventions: Device: Penumbra System | Intervention Type: DRUG; Name: intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV rtPA | Intervention Type: DEVICE; Name: Penumbra System; Assigned to Arm(s): IV rtPA and IA Penumbra System

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset
Brief Summary: To evaluate the hypothesis that mechanical embolectomy with the Solitaire FR device is superior to medical management alone in achieving favorable outcome in the distribution of the modified Rankin Scale scores at 90 days in subjects presenting with acute large vessel ischemic stroke \< 8 hours from symptom onset.


Options:
A: Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Solitaire FR device | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: DEVICE; Name: Solitaire FR device; Assigned to Arm(s): Endovascular treatment | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Meibum lipids are modified in patients with MGD, resulting in tear instability, evaporative dry eye, and eyelid inflammation. These changes add to corneal damages and exacerbate ocular symptoms, which are all associated with the constant release of inflammatory mediators. To our knowledge, there has been no study on tear cytokine levels in MGD patients treated with topical loteprednol etabonate. The investigators, thus, evaluated both inflammatory tear cytokine levels and corresponding clinical outcomes for analyzing the efficacy of topical loteprednol etabonate in moderate and severe MGD. The aim of this research was to determine the concentration of inflammatory tear cytokines in patients with MGD and to compare the changes in tear cytokine levels between topical loteprednol etabonate and warm compress treatment group and warm compress only treatment group.


Options:
A: Arm Label: Lotemax with warm compress group; Type: EXPERIMENTAL; Interventions: Drug: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage | Arm Label: warm compress only group; Type: ACTIVE_COMPARATOR; Interventions: Other: warm compress only group | Intervention Type: DRUG; Name: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage; Assigned to Arm(s): Lotemax with warm compress group | Intervention Type: OTHER; Name: warm compress only group; Assigned to Arm(s): warm compress only group
B: Arm Label: intense; Type: EXPERIMENTAL; Interventions: Drug: Softacort | Arm Label: standard; Type: EXPERIMENTAL; Interventions: Drug: Softacort | Intervention Type: DRUG; Name: Softacort; Assigned to Arm(s): intense, standard
C: Arm Label: KPI-121 0.25% Ophthalmic Suspension; Type: ACTIVE_COMPARATOR; Interventions: Drug: KPI-121 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KPI-121; Assigned to Arm(s): KPI-121 0.25% Ophthalmic Suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vehicle
D: Intervention Type: DRUG; Name: Lotemax; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Restasis; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
Brief Summary: Improved methods are needed to monitor patients with inflammatory bowel disease. Telemedicine has shown promise in patients with other chronic diseases; pilot testing in our patients with inflammatory bowel disease demonstrated that the technology was feasible and improved clinical outcomes.

The telemedicine system for patients with inflammatory bowel disease (Tele-IBD) should improve outcomes for patients, improve access to care in areas with limited resources, and decrease health care costs.


Options:
A: Arm Label: face-to-face consultations; Type: ACTIVE_COMPARATOR; Interventions: Other: face-to-face consultations | Arm Label: telephone consultations; Type: EXPERIMENTAL; Interventions: Other: telephone consultations | Intervention Type: OTHER; Name: telephone consultations; Assigned to Arm(s): telephone consultations | Intervention Type: OTHER; Name: face-to-face consultations; Assigned to Arm(s): face-to-face consultations
B: Arm Label: Telemedicine group; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Telephone support group; Type: EXPERIMENTAL; Interventions: Device: Telephone | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine group | Intervention Type: DEVICE; Name: Telephone; Assigned to Arm(s): Telephone support group | Intervention Type: OTHER; Name: Conventional care; Assigned to Arm(s): Control group
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: myIBDcoach; Type: EXPERIMENTAL; Interventions: Other: myIBDcoach | Intervention Type: OTHER; Name: myIBDcoach; Assigned to Arm(s): myIBDcoach | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Weekly Home Monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Arm Label: Home Monitoring Every Other Week; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Weekly Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring Every Other Week

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
Brief Summary: Improved methods are needed to monitor patients with inflammatory bowel disease. Telemedicine has shown promise in patients with other chronic diseases; pilot testing in our patients with inflammatory bowel disease demonstrated that the technology was feasible and improved clinical outcomes.

The telemedicine system for patients with inflammatory bowel disease (Tele-IBD) should improve outcomes for patients, improve access to care in areas with limited resources, and decrease health care costs.


Options:
A: Arm Label: Educational Video; Type: EXPERIMENTAL; Interventions: Other: Educational video | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational video; Assigned to Arm(s): Educational Video
B: Arm Label: Group 1 (IBD Nurse CONSULT + BOOKLET); Type: EXPERIMENTAL; Interventions: Other: IBD nurse intervention | Arm Label: Group 2 (BOOKLET alone); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: IBD nurse intervention; Assigned to Arm(s): Group 1 (IBD Nurse CONSULT + BOOKLET)
C: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Weekly Home Monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Arm Label: Home Monitoring Every Other Week; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Weekly Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring Every Other Week
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: myIBDcoach; Type: EXPERIMENTAL; Interventions: Other: myIBDcoach | Intervention Type: OTHER; Name: myIBDcoach; Assigned to Arm(s): myIBDcoach | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease
Brief Summary: The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to generate data supporting that the efficacy and safety under treatment with HX575 and Epogen®/Procrit® are comparable.


Options:
A: Arm Label: ESAs 1 low dose; Type: EXPERIMENTAL; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Arm Label: ESAs 2 high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 1 low dose | Intervention Type: DRUG; Name: Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.; Assigned to Arm(s): ESAs 2 high dose
B: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
D: Arm Label: HX575 epoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: HX575 epoetin alfa | Arm Label: US-licensed epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: US-licensed epoetin alfa | Intervention Type: DRUG; Name: HX575 epoetin alfa; Assigned to Arm(s): HX575 epoetin alfa | Intervention Type: DRUG; Name: US-licensed epoetin alfa; Assigned to Arm(s): US-licensed epoetin alfa

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects in Cape Town, South Africa
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine LAM test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to evaluate the accuracy and diagnostic yield of the Cepheid Xpert MTB/Rif test in detecting tuberculosis in the blood of HIV-infected adults.


Options:
A: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
C: N/A
D: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects in Cape Town, South Africa
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine LAM test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to evaluate the accuracy and diagnostic yield of the Cepheid Xpert MTB/Rif test in detecting tuberculosis in the blood of HIV-infected adults.


Options:
A: N/A
B: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
C: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
D: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects in Cape Town, South Africa
Brief Summary: The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine LAM test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to evaluate the accuracy and diagnostic yield of the Cepheid Xpert MTB/Rif test in detecting tuberculosis in the blood of HIV-infected adults.


Options:
A: Arm Label: Smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear | Arm Label: GeneXpert; Type: EXPERIMENTAL; Interventions: Other: Xpert | Intervention Type: OTHER; Name: Xpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: Smear; Assigned to Arm(s): Smear
B: Arm Label: Case detection group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Arm Label: Drug resistance risk group; Type: N/A; Interventions: Device: Investigational Xpert DST test | Intervention Type: DEVICE; Name: Investigational Xpert DST test; Assigned to Arm(s): Case detection group, Drug resistance risk group
C: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection
B: Arm Label: Reference Drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Tested Drug; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Reference Drug | Intervention Type: DRUG; Name: Triamcinolone; Assigned to Arm(s): Tested Drug
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
D: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg

Answer: A